The SELECT Trial and Differentiated Thyroid Cancer

home / investigator-perspectives / the-select-trial-and-differentiated-thyroid-cancer

Lori Wirth, MD provides an overview of differentiated thyroid cancer and reviews key data from the SELECT trial examining the use of lenvatinib.

Lori J. Wirth, MD

EP. 1: Overview and Diagnosis of Differentiated Thyroid Cancer

Lori J. Wirth, MD
June 25th 2021

Lori Wirth, MD, provides an overview and diagnosis consideration of differentiated thyroid cancer and its related subtypes.

Watch

Lori J. Wirth, MD

EP. 2: Treatment Options for Patients With Differentiated Thyroid Cancer

Lori J. Wirth, MD
June 25th 2021

Lori Wirth, MD, discusses treatment options and potential adverse effects for differentiated thyroid cancer.

Watch

Lori J. Wirth, MD

EP. 3: Treatment Options for Patients With Radioiodine-Refractory Metastatic Disease

Lori J. Wirth, MD
June 25th 2021

Medical oncologist Lori Wirth, MD, discusses treatment options for patients with radioiodine-refractory metastatic disease.

Watch

Lori J. Wirth, MD

EP. 4: Clinical Practice Implications From the SELECT Trial

Lori J. Wirth, MD
June 25th 2021

An overview of how SELECT trial data affected clinical treatment practice for patients with differentiated thyroid cancer.

Watch

Lori J. Wirth, MD

EP. 5: Post Hoc Analysis of Patients With Lung Metastases from the SELECT Trial

Lori J. Wirth, MD
June 25th 2021

Lori Wirth, MD, reviews key efficacy data from the post hoc analysis of the SELECT trial investigating the use of lenvatinib in patients with lung metastases.

Watch

Lori J. Wirth, MD

EP. 6: Future Considerations in the Management of Differentiated Thyroid Cancer

Lori J. Wirth, MD
June 25th 2021

Lori Wirth, MD, discusses unmet needs and future considerations in the management of differentiated thyroid cancer.

Watch